Mexico Strengthens Equity in Access to Hemophilia Care

The Federation seeks to promote the creation of hemophilia clinics in hospitals across different states, with the goal of preventing patients from having to travel to Mexico City. Although he acknowledged that not all patients are candidates and that the cost remains a challenge, he stated that Mexico has already begun to incorporate innovations that allow for personalized treatment regimens, with monthly or even more spaced-out applications. Finally, Victor Manuel Losada made a direct call to patients and families: in the event of unusual bleeding, frequent bruises, or complications from medical procedures, to immediately see a hematologist. He emphasized that Mexico already uses recombinant products and synthetic molecules, which reduces the risk of infections such as HIV or hepatitis. Regarding the future, Losada pointed out that new therapies and the development of gene therapy are transforming the landscape of hemophilia. These clinics will be staffed by multidisciplinary teams led by hematologists, but also integrating traumatologists, orthopedists, rehabilitation specialists, gynecologists, psychologists, and increasingly, geriatricians, given the increased life expectancy for people with hemophilia. Losada explained that thanks to prophylaxis and modern therapies, the life profile of patients has changed radically: from a life expectancy of 15 or 20 years in the 1960s, today there are people with hemophilia who live past 80. He stressed that today there are accessible diagnostics and effective treatments, and that the Federation keeps its doors open to guide, accompany, and refer patients throughout the country through its 23 affiliated associations. This note, as well as reports, exclusive interviews, videos, podcasts and more, you will find in our next special digital edition of 'Temas Selectos en Hematología' on LaSalud.mx, The Journal of the Medical Community. Visit some of our special editions at https://issuu.com/grupo-mundodehoy. D.E. How to strengthen equity in access to hemophilia care. By: Carlos Henze / Photography: Daniela Escartin. LaSalud.mx/Hematologia.mx, Mexico City, January 30, 2026. - The formalization of Victor Manuel Losada López's appointment as president of the Mexican Republic Hemophilia Federation (FHRM) took place during the XXVI National Hemophilia Congress, held last August, in a context marked by the need to strengthen timely diagnosis, comprehensive care, and equity in access to treatments for a rare disease that, although historically overlooked, has a growing impact on public health and the quality of life for thousands of families in the country. In an exclusive conversation with LaSalud.mx/Hematologia.mx, Victor Manuel Losada, president of the Mexican Republic Hemophilia Federation, explained that his administration will be guided by an annual national work plan aligned with the World Federation of Hemophilia, with clear priorities: to increase the visibility of women with hemophilia, expand the national patient registry, and decentralize care through the creation of specialized clinics in the states of the Republic. One of the most relevant axes of this new stage is the recognition that women are not just carriers, but also symptomatic patients with bleeding, micro-hemorrhages, and joint damage that were historically undiagnosed. Losada emphasized that this is not about a new epidemic, but about making visible a reality that has always existed, which now demands specific diagnostic protocols, gynecological follow-up, and comprehensive care. Currently, the FHRM has a registry of 7,200 people with different coagulopathies, a database considered reliable and frequently requested by health institutions and authorities. This change forces a rethinking of care, not only from the control of bleeding, but from the approach to comorbidities, mental health, rehabilitation, and aging. In terms of access to treatments, the president of the FHRM highlighted the constant work with the IMSS, the ISSSTE, the Ministry of Health, and the General Health Council to guarantee the continuity of supply and prevent setbacks to obsolete therapies such as cryoprecipitates or plasma. Expanding and strengthening this registry is key to having more weight when dealing with federal and state health authorities. The decentralization of care is another of the strategic projects. However, the president acknowledged that there is a significant under-registration, both in men and women, which limits the planning of public policies and equitable access to specialized services.